Scope
The National Cancer Grid’s May 2021 palliative-care pathway addresses malignant bowel obstruction through cause assessment, shared goals, symptom relief and selective procedures. It distinguishes incomplete obstruction without colic from complete obstruction, with treatment adjusted to symptoms and goals of care. This summary covers assessment and symptom-management principles without providing a complete drug-dosing or procedural protocol.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Establish the cause and goals of care
- Consider nonmalignant comorbidity as a cause of upper gastrointestinal obstruction symptoms. When history or examination suggests peptic ulcer disease or chronic pancreatitis, manage or refer for the relevant medical assessment. [1]
- Check for faecal impaction and long-standing constipation as contributors to obstruction symptoms. The pathway links that assessment to the constipation protocol rather than treating every episode as irreversible malignant obstruction. [1]
- Use CT when a corrective measure is feasible and could improve quality of life; the source describes its role in distinguishing mechanical from functional obstruction and identifying single-site versus multisite disease. [1]
- Assess the patient’s understanding and discuss prognosis and care options with the patient and family. Document supported shared decisions, including views about palliative surgery, preferred care setting, hydration and nutrition. [1]
Address pain, secretions and reversible bowel-wall swelling
- Use opioids for persistent pain from cancer infiltration. The medication section presents several routes and titration examples; selection still needs to match the patient’s clinical circumstances. [1]
- Anticholinergic and antisecretory treatment is intended to reduce distension and intermittent colicky or spasmodic pain. Keep that symptom goal distinct from treatment of persistent infiltration pain. [1]
- If dexamethasone is used as the anti-inflammatory component, stop it if there is no improvement within 5 days or if adverse effects occur. If obstructive symptoms improve, the document advises gradual withdrawal over 2 weeks. [1]
Distinguish prokinetic from non-prokinetic antiemetics
- For incomplete obstruction without colic, prokinetics may be used with monitoring. If colic returns, use the complete-obstruction pathway; stop prokinetic antiemetics if colic develops or vomiting worsens. [1]
- In complete malignant bowel obstruction, use an antiemetic without prokinetic action. The medication section lists haloperidol and cyclizine as non-prokinetic options and allows their combination. [1]
- For hydration and electrolyte correction, the medication section limits hydration to significant dehydration and calls for monitoring for third-space expansion. Discuss the potential benefit and burden of parenteral hydration with the patient and family. [1]
Relieve distress and involve the wider team
- Teach mouth care to help thirst, oral discomfort and nausea. The source describes a lukewarm salt-and-soda water approach as part of symptom support. [1]
- Provide emotional support to both the patient and family. Where end-of-life care is appropriate, include symptom relief, preparation and spiritual or religious concerns in the care plan. [1]
- Involve a dietitian for advice on small-volume, low-residue intake and feeding options. Nursing input should address care for a bedbound patient, feeding support and procedures. [1]
Consider procedures in the context of agreed goals
- Palliative procedures listed in the guideline include colostomy, ileostomy, feeding jejunostomy and venting gastrostomy. Consider their appropriateness through the documented goals-of-care discussion rather than assuming a single intervention fits all malignant obstructions. [1]
- For associated ascites, make a considered decision about paracentesis using the linked NCG ascites guidance. The bowel-obstruction chapter does not itself provide the full ascites procedure protocol. [1]
Limitations and use
- The source was released in May 2021. This summary does not establish current availability or regulatory status of every medicine in its tables.
- Inconsistent octreotide dose ranges and unclear drug or formulation instructions prevent a complete dosing protocol. Detailed procedure instructions are also omitted.
- Linked constipation, ascites and end-of-life guidance are separate sources; their full recommendations are not contained in this summary.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Approach to managing Malignant Bowel Obstruction
Selected recommendation material consulted
Publication details
- Issuing organisation
- NCG
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- India
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.